HMB Supplementation and Motor Performance in Sarcopenic Patiens

Launched by FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS · Jan 24, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a nutritional supplement called HMB on muscle strength and performance in older adults who have sarcopenia, a condition characterized by the loss of muscle mass and strength as people age. The researchers want to see if taking HMB can help slow down the progression of sarcopenia and improve overall physical function, which is important for maintaining independence and quality of life.

To participate in this trial, individuals must be between 50 and 99 years old and have a diagnosis of sarcopenia based on specific criteria, such as having low muscle mass and strength. Participants should be able to walk independently or with minimal assistance and have experienced at least five days of bed rest. Those with certain health conditions, such as kidney or liver diseases, or who are taking specific medications, may not be eligible to join. If you qualify and decide to participate, you can expect to follow simple instructions and guidance from a physiotherapist as part of the study. This trial is not yet recruiting, but it aims to help improve understanding and treatment options for sarcopenia in older adults.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age between 50 and 99 years;
• * Diagnosis of sarcopenia according to the criteria of the European Working Group on Sarcopenia in Older People (EWGSOP) (Cruz-Jentoft et al., 2018; Kirk et al., 2024), specifically:
• • Reduced muscle mass, assessed through bioelectrical impedance analysis (Skeletal Mass Index/height value of ≤ 7.0 kg/m² for men and ≤ 5.5 kg/m² for women);
• • Reduced muscle strength, assessed through the Hand Grip Strength Test (value \< 27 kg for men and \< 16 kg for women);
• • Reduced physical performance, assessed through gait speed (≤ 0.8 m/s in the 4-meter walking test) and the Short Physical Performance Battery (score ≤ 8).
• • Cognitive abilities sufficient to follow simple instructions and understand the physiotherapist's guidance (assessed using the Mini Mental State Examination, with a corrected score between 22 and 27).
• • Ability to walk independently or with minimal assistance;
• • A history of bed rest lasting at least 5 days;
• • Ability to understand and sign the informed consent form.
• Exclusion Criteria:
• • Presence of a known or suspected allergy/intolerance to one or more ingredients of Myosave;
• • Presence of kidney or liver diseases;
• • Use of anticoagulant or antiplatelet drugs;
• • Presence of uncontrolled hypertension or diabetes;
• • Oncological diseases, orthopedic or postural issues, presence of plantar ulcers;
• • Partial or total amputation of foot segments;
• • Inability to provide informed consent.